Two Decades of Stroke Prevention in China

doi:10.3969/j.issn.1673-5765.2025.05.006

Abstract

Abstract: Preventing the occurrence of stroke is the fundamental approach to reducing the burden of stroke disease. As a disease caused by multiple factors, the pathogenesis of stroke involves various risk factors such as lifestyle, genetics, and the environment. Controlling risk factors is the core strategy for reducing the incidence of stroke. Both primary prevention for the non-diseased population and secondary prevention for stroke patients hold significant value in stroke prevention and management. This article systematically reviews the development of stroke prevention in China over the past two decades, focusing on the following three research achievements: first, it summarizes the epidemiological trends and changing characteristics of major stroke risk factors in China based on epidemiological data; second, it examines the implementation of pharmacological interventions in secondary prevention of stroke, with a specific focus on the progress of antiplatelet therapy, and reviews the landmark clinical studies in the field of stroke prevention and their guiding value for clinical practice; finally, it provides a comprehensive review and summary of the evolution of China’s stroke screening system and prevention and control strategies. In addition, this article also looks forward to the future development of stroke prevention technology and research directions: emerging technologies such as wearable medical devices and artificial intelligence-assisted decision-making provide new technical means for stroke prevention. However, the application effects and promotional value of these new technologies still need to be further validated by large-scale clinical studies.

Key words: Stroke; Prevention; Primary prevention; Secondary prevention

摘要： 预防卒中发生是降低卒中疾病负担的根本途径。作为多因素共同作用所致疾病，卒中的发病机制涉及生活方式、遗传及环境等多种危险因素，控制危险因素是降低卒中发病率的核心策略。无论是针对未患病群体的卒中一级预防，还是针对卒中患者的二级预防，在卒中防治管理中都具有重要价值。本文系统梳理中国近20年来卒中预防的发展历程，重点呈现以下3方面研究成果：基于流行病学数据，系统总结中国卒中重要危险因素的流行趋势及变化特征；总结卒中二级预防中药物干预的执行情况，重点介绍抗血小板治疗的进展，回顾卒中预防领域具有里程碑意义的临床研究及其对临床实践的指导价值；总结和描述中国卒中筛查体系及防控策略的演进路径。此外，本文还对未来的卒中预防技术发展和研究方向进行展望：可穿戴医疗设备、人工智能辅助决策等新兴技术为卒中预防提供了新的工具，但这些新技术的应用效果及推广价值仍有待大规模临床研究进一步验证。

关键词: 卒中; 预防; 一级预防; 二级预防

CLC Number:

ZHANG Runhua, LI Tianqi, ZHAI Yi, JIANG Yong, LIU Gaifen. Two Decades of Stroke Prevention in China[J]. Chinese Journal of Stroke, 2025, 20(5): 581-594.

张润华, 李天琪, 翟屹, 姜勇, 刘改芬. 中国卒中预防20年[J]. 中国卒中杂志, 2025, 20(5): 581-594.

References

[1] 王拥军，李子孝，谷鸿秋，等. 中国卒中报告2019（中文版）（1）[J]. 中国卒中杂志，2020，15（10）：1037-1043.
WANG Y J，LI Z X，GU H Q，et al. China stroke statistics 2019（1）[J]. Chin J Stroke，2020，15（10）：1037-1043.
[2] HAN Y T，HU Y Z，YU C Q，et al. Lifestyle，cardiometabolic disease，and multimorbidity in a prospective Chinese study[J]. Eur Heart J，2021，42（34）：3374-3384.
[3] MA Q F，LI R，WANG L J，et al. Temporal trend and attributable risk factors of stroke burden in China，1990—2019：an analysis for the global burden of disease study 2019[J/OL]. Lancet Public Health，2021，6（12）：e897-e906[2025-02-20]. https://doi.org/10.1016/S2468-2667 (21) 00228-0.
[4] ZHANG M，SHI Y，ZHOU B，et al. Prevalence，awareness，treatment，and control of hypertension in China，2004—2018：findings from six rounds of a national survey[J/OL]. BMJ，2023，380：e071952[2025-02-20]. https://doi.org/10.1136/bmj-2022-071952.
[5] NCD Risk Factor Collaboration（NCD-RisC）. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019：a pooled analysis of 1201 population-representative studies with 104 million participants[J]. Lancet，2021，398（10304）：957-980.
[6] YANG W Y，LU J M，WENG J P，et al. Prevalence of diabetes among men and women in China[J]. N Engl J Med ，2010，362（12）：1090-1101.
[7] XU Y，WANG L M，HE J，et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA，2013，310（9）：948-959.
[8] WANG L M，PENG W，ZHAO Z P，et al. Prevalence and treatment of diabetes in China，2013—2018[J]. JAMA，2021，326（24）：2498-2506.
[9] HE J，GU D F，REYNOLDS K，et al. Serum total and lipoprotein cholesterol levels and awareness，treatment，and control of hypercholesterolemia in China[J]. Circulation，2004，110（4）：405-411.
[10] YANG W Y，XIAO J Z，YANG Z J，et al. Serum lipids and lipoproteins in Chinese men and women[J]. Circulation，2012，125（18）：2212-2221.
[11] 李剑虹，王丽敏，米生权，等. 2010年我国成年人血脂异常知晓率和治疗率及控制率调查[J]. 中华预防医学杂志，2012，46（8）：687-691.
LI J H，WANG L M，MI S Q，et al. Awareness rate，treatment rate and control rate of dyslipidemia in Chinese adults，2010[J]. Chin J Pre Med，2012，46（8）：687-691.
[12] ZHANG M，PENG K，ZHANG X，et al. Geographic variations in the prevalence，awareness，treatment，and control of dyslipidemia among Chinese adults in 2018—2019：a cross-sectional study[J]. Biomed Environ Sci，2023，36（4）：313-323.
[13] WANG L M，ZHOU B，ZHAO Z P，et al. Body-mass index and obesity in urban and rural China：findings from consecutive nationally representative surveys during 2004—2018[J]. Lancet，2021，398（10294）：53-63.
[14] ZHANG M，YANG L，WANG L M，et al. Trends in smoking prevalence in urban and rural China，2007 to 2018：findings from 5 consecutive nationally representative cross-sectional surveys[J/OL]. PLoS Med，2022，19（8）：e1004064[2025-02-20]. https://doi.org/10.1371/journal.pmed.1004064.
[15] 中国疾病预防控制中心慢性非传染性疾病预防控制中心. 中国慢性病及其危险因素监测分析报告2004[M]. 北京：中国协和医科大学出版社，2009.
Chronic Non-Communicable Disease Prevention and Control Center，Chinese Center for Disease Control and Prevention. Report on chronic disease risk factor surveillance in China 2004[M]. Beijing：Peking Union Medical College Press，2009.
[16] 中国疾病预防控制中心慢性非传染性疾病预防控制中心. 中国慢性病及其危险因素监测报告2007[M]. 北京：人民卫生出版社，2010.
Chronic Non-Communicable Disease Prevention and Control Center，Chinese Center for Disease Control and Prevention. Report on chronic disease risk factor surveillance in China 2007[M]. Beijing：People’s Medical Publishing House，2010.
[17] 中国疾病预防控制中心，中国疾病预防控制中心慢性非传染性疾病预防控制中心. 中国慢性病及其危险因素监测报告2010[M]. 北京：军事医学科学出版社，2012.
Chinese Center for Disease Control and Prevention；Chronic Non-Communicable Disease Prevention and Control Center，Chinese Center for Disease Control and Prevention. Report on chronic disease risk factor surveillance in China 2010[M]. Beijing：Military Medical Science Press，2012.
[18] 中国疾病预防控制中心，中国疾病预防控制中心慢性非传染性疾病预防控制中心. 中国慢性病及其危险因素监测报告2013[M]. 北京：军事医学科学出版社，2016.
Chinese Center for Disease Control and Prevention；Chronic Non-communicable Disease Prevention and Control Center，Chinese Center for Disease Control and Prevention. Report on chronic disease risk factor surveillance in China 2013[M]. Beijing：Military Medical Science Press，2016.
[19] 中国疾病预防控制中心，中国疾病预防控制中心慢性非传染性疾病预防控制中心. 中国慢性病及危险因素监测报告2018[M]. 北京：人民卫生出版社，2021.
Chinese Center for Disease Control and Prevention；Chronic Non-Communicable Disease Prevention and Control Center，Chinese Center for Disease Control and Prevention. Report on chronic disease risk factor surveillance in China 2018[M]. Beijing：People’s Medical Publishing House，2021.
[20] BUSHNELL C，KERNAN W N，SHARRIEF A Z，et al. 2024 guideline for the primary prevention of stroke：a guideline from the American Heart Association/American Stroke Association[J/OL]. Stroke，2024，55（12）：e344-e424[2025-02-20]. https://doi.org/10.1161/STR.0000000000000475.
[21] 刘晨一，王丽敏，高星星，等. 蔬菜和水果摄入与心脑血管疾病关系的研究进展[J]. 中华流行病学杂志，2023，44（2）：348-352.
LIU C Y，WANG L M，GAO X X，et al. Research progress on the relationship between vegetables and fruit intake on cardio-cerebrovascular diseases[J]. Chin J Epidemiol，2023，44（2）：348-352.
[22] LI Z X，WANG C J，ZHAO X Q，et al. Substantial progress yet significant opportunity for improvement in stroke care in China[J]. Stroke，2016，47（11）：2843-2849.
[23] WANGQIN R Q，LASKOWITZ D T，WANG Y J，et al. International comparison of patient characteristics and quality of care for ischemic stroke：analysis of the China national stroke registry and the American Heart Association get with the guidelines—stroke program[J/OL]. J Am Heart Assoc，2018，7（20）：e010623[2025-02-20]. https://doi.org/10.1161/JAHA.118.010623.
[24] GU H Q，YANG X，WANG C J，et al. Clinical characteristics，management，and in-hospital outcomes in patients with stroke or transient ischemic attack in China[J/OL]. JAMA Netw Open，2021，4（8）：e2120745[2025-02-20]. https://doi.org/10.1001/jamanetworkopen.2021.20745.
[25] 王拥军，李子孝，谷鸿秋，等. 中国卒中报告2020（中文版）（2）[J]. 中国卒中杂志，2022，17（6）：553-567.
WANG Y J，LI Z X，GU H Q，et al. China stroke statistics 2020（2）[J]. Chin J Stroke，2022，17（6）：553-567.
[26] ZHANG L，SHI J F，PAN Y S，et al. Secondary prevention medication persistence and prognosis of acute ischaemic stroke or transient ischaemic attack[J]. Stroke Vasc Neurol，2021，6（3）：376-383.
[27] JIANG Y，YANG X M，LI Z X，et al. Persistence of secondary prevention medication and related factors for acute ischemic stroke and transient ischemic attack in China[J]. Neurol Res，2017，39（6）：492-497.
[28] 陈艳雪，姜悦，李子孝，等. 中国急性缺血性卒中及短暂性脑缺血发作二级预防药物依从性的现状[J]. 中国卒中杂志，2018，13（7）：686-691.
CHEN Y X，JIANG Y，LI Z X，et al. Current status of medication compliance in secondary prevention for ischemic stroke or transient ischemic attack[J]. Chin J Stroke，2018，13（7）：686-691.
[29] SACCO R L，DIENER H C，YUSUF S，et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke[J]. N Engl J Med，2008，359（12）：1238-1251.
[30] The SPS3 Investigators. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke[J]. N Engl J Med，2012，367（9）：817-825.
[31] FURIE K L，KASNER S E，ADAMS R J，et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack：a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke，2011，42（1）：227-276.
[32] WANG Y J，WANG Y L，ZHAO X Q，et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack[J]. N Engl J Med ，2013，369（1）：11-19.
[33] FISHER M，SEASTRONG R. The past decade at Stroke：important advances and overcoming challenges[J]. Stroke，2020，51（3）：1032-1035.
[34] WANG Y J，MENG X，WANG A X，et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA[J]. N Engl J Med ，2021，385（27）：2520-2530.
[35] GBD 2021 Stroke Risk Factor Collaborators. Global，regional，and national burden of stroke and its risk factors，1990—2021：a systematic analysis for the global burden of disease study 2021[J]. Lancet Neurol，2024，23（10）：973-1003.
[36] 中华医学会物理医学与康复学分会. 卫生部脑卒中筛查与防治工程介绍[EB/OL].（2011-04-26）[2025-02-20]. https://cspmr.cma.org.cn/cn/news.asp?id=329.html.
[37] 巢宝华，刘建民，王伊龙，等. 中国脑卒中防治：成就、挑战和应对[J]. 中国循环杂志，2019，34（7）：625-631.
CHAO B H，LIU J M，WANG Y L，et al. Stroke prevention and control in China：achievements，challenges and responses[J]. Chinese Circulation Journal，2019，34（7）：625-631.
[38] 王陇德，刘建民，杨弋，等. 《中国脑卒中防治报告2017》概要[J]. 中国脑血管病杂志，2018，15（11）：611-617.
WANG L D，LIU J M，YANG Y，et al. Brief report on stroke prevention and treatment in China，2017[J]. Chin J Cerebrovasc Dis，2018，15（11）：611-617.
[39] 《中国脑卒中防治报告2021》编写组. 《中国脑卒中防治报告2021》概要[J]. 中国脑血管病杂志，2023，20（11）：783-793.
Report on Stroke Prevention and Treatment in China Writing Group. Brief report on stroke prevention and treatment in China，2021[J]. Chin J Cerebrovasc Dis，2023，20（11）：783-793.
[40] 中共中央国务院印发《“健康中国2030”规划纲要》[EB/OL].（2016-10-25）[2025-02-20]. https://www.gov.cn/zhengce/202203/content_3635233.htm.
[41] 国家卫生和计划生育委员会办公厅，国家中医药管理局办公室. 国家卫生计生委办公厅国家中医药管理局办公室关于印发脑卒中综合防治工作方案的通知[EB/OL].（2016-12-09）[2025-02-20]. https://www.gov.cn/xinwen/2016-12/09/content_5145774. htm.
[42] 国家卫生健康委员会办公厅. 国家卫生健康委办公厅关于印发上消化道癌人群筛查及早诊早治等技术方案的通知[EB/OL].（2019-06-18）[2025-02-20]. http://www.nhc.gov.cn/jkj/s7930/201906/50f8c202839a4b1c9afd81441e1b88af.shtml.
[43] 健康中国行动推进委员会. 健康中国行动（2019—2030年）[EB/OL].（2019-07-15）[2025-02-20]. https://www.gov.cn/xinwen/2019-07/15/content_5409694.htm.
[44] 国务院办公厅. 国务院办公厅关于印发中国防治慢性病中长期规划（2017—2025年）的通知[EB/OL].（2017-02-14）[2025-02-20]. https://www.gov.cn/zhengce/content/2017-02/14/content_5167886.htm.
[45] 中华医学会糖尿病学分会，国家基层糖尿病防治管理办公室. 国家基层糖尿病防治管理指南（2022）[J]. 中华内科杂志，2022，61（3）：249-262.
Chinese Diabetes Society，National Office for Primary Diabetes Care. National guidelines for the prevention and control of diabetes in primary care（2022）[J]. Chin J Intern Med，2022，61（3）：249-262.
[46] 中国血脂管理指南修订联合专家委员会. 中国血脂管理指南（基层版2024年）[J]. 中国循环杂志，2024，39（4）：313-321.
Joint Committee on the Chinese Guidelines for Lipid Management. Chinese guideline for lipid management（primary care version 2024）[J]. Chinese Circulation Journal，2024，39（4）：313-321.
[47] “三高”共管规范化诊疗中国专家共识（2023版）专家组. “三高”共管规范化诊疗中国专家共识（2023版）[J/OL]. 中华心血管病杂志（网络版），2023，6（1）：1-11[2025-02-20]. https://doi.org/10.3760/cma.j.cn116031.2023.1000144.
Writing Group of 2023 Chinese Expert Consensus on the Standardized Diagnosis and Treatment of the Co-management of Hypertension，Hyperglycemia and Dyslipidemia. 2023 Chinese expert consensus on the standardized diagnosis and treatment of the co-management of hypertension，hyperglycemia and dyslipidemia[J/OL]. Chinese Video Journal of Cardiology，2023，6（1）：1-11[2025-02-20]. https://doi.org/10.3760/cma.j.cn116031.2023.1000144.
[48] 国务院. 国务院关于实施健康中国行动的意见[EB/OL].（2019-07-15）[2025-02-20]. https://www.gov.cn/zhengce/content/2019-07/15/content_5409492.htm.
[49] 国家卫生健康委员会，教育部，工业和信息化部，等. 关于印发加强脑卒中防治工作减少百万新发残疾工程综合方案的通知[EB/OL].（2021-06-18）[2025-02-20]. http://www.nhc.gov.cn/yzygj/s7659/202106/57ccc3798e1d4a2087fb1a46acafd1e2.shtml.
[50] 国家卫生健康委员会，国家发展和改革委员会，教育部，等. 关于印发健康中国行动—心脑血管疾病防治行动实施方案（2023—2030年）的通知[EB/OL].（2023-10-30）[2025-02-20]. https://www.gov.cn/zhengce/zhengceku/202311/content_6915365.htm.
[51] LI X Z，JIN T Y，BAI C，et al. Analysis of stroke burden in China from 1990 to 2021 and projections for the next decade[J/OL]. Neuroepidemiology，2024：1-12[2025-02-20]. https://doi.org/10.1159/000542487.
[52] 中国高血压防治指南修订委员会，高血压联盟（中国），中国医疗保健国际交流促进会高血压病学分会，等. 中国高血压防治指南（2024年修订版）[J]. 中华高血压杂志（中英文），2024，32（7）：603-700.
Writing Group of 2024 Chinese Guidelines for the Management of Hypertension，Chinese Hypertension League，Hypertension Branch of China International Exchange and Promotive Association for Medical and Health Care，et al. 2024 Chinese guidelines for the management of hypertension[J]. Chin J Hypertens，2024，32（7）：603-700.
[53] 顾景范. 《中国居民营养与慢性病状况报告（2015）》解读[J]. 营养学报，2016，38（6）：525-529.
GU J F. Interpretation of report on nutrition and chronic diseases of Chinese residents（2015）[J]. Acta Nutrimenta Sinica，2016，38（6）：525-529.
[54] 于长申，巫嘉陵. 人工智能在脑卒中管理中的研究进展[J]. 中国现代神经疾病杂志，2021，21（1）：14-20.
YU C S，WU J L. Research progress of artificial intelligence in stroke management[J]. Chin J Contemp Neurol Neurosurg，2021，21（1）：14-20.
[55] LI J，HUANG J，ZHENG L B，et al. Application of artificial intelligence in diabetes education and management：present status and promising prospect
[J/OL]. Front Public Health，2020，8：173[2025-02-20]. https://doi.org/10.3389/fpubh.2020.00173.
[56] LIU Y L，ZHANG Q，ZHAO G，et al. Deep learning-based method of diagnosing hyperlipidemia and providing diagnostic markers automatically[J/OL]. Diabetes，Metab Syndr Obes，2020，13：679-691
[2025-02-20]. https://doi.org/10.2147/DMSO.S242585.
[57] 张思琪，杨添淞，马帅，等. 深度学习在脑卒中诊断与防治中的研究进展[J]. 磁共振成像，2022，13（11）：125-128.
ZHANG S Q，YANG T S，MA S，et al. Research progress of deep learning in stroke diagnosis and prevention[J]. Chin J Magn Reson Imaging，2022，13（11）：125-128.
[58] LIU J，SODINI C G，OU Y H，et al. Feasibility of fingertip oscillometric blood pressure measurement：model-based analysis and experimental validation[J]. IEEE J Biomed Health Inform，2020，24（2）：533-542.
[59] PAN H Y，LEE C K，LIU T Y，et al. The role of wearable home blood pressure monitoring in detecting out-of-office control status[J]. Hypertens Res，2024，47（4）：1033-1041.